Incyte
Incyte is a global biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics. The company focuses on three core therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its primary value proposition lies in its ability to bring first-in-class and best-in-class treatments to market for rare blood cancers and immune-related conditions.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Hematology
primaryThis segment focuses on rare blood cancers and conditions related to hematopoietic stem cell transplants. It includes the company's most significant commercial products and a robust pipeline of clinical candidates for myeloproliferative neoplasms.
JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix), MINJUVI (tafasitamab), NIKTIMVO (axatilimab-csfr)
Specialty pharmacies, Wholesalers, Hospitals, Oncology clinics
Oncology
majorDedicated to the development of proprietary therapeutics for various solid tumors and hematologic malignancies. This segment leverages the company's expertise in kinase inhibition and immunotherapy.
PEMAZYRE (pemigatinib)
Specialty pharmacies, Wholesalers, Cancer treatment centers
Inflammation and Autoimmunity (IAI)
majorFocuses on developing treatments for dermatologic and other immune-mediated inflammatory diseases. This segment represents a significant growth area for the company's topical and systemic therapies.
OPZELURA (ruxolitinib) cream
Dermatologists, Specialty pharmacies, Wholesalers
Segment Financials
MINJUVI/MONJUVI — Total revenues
View metricICLUSIG — Total revenues
View metricJAKAVI Royalty Revenues — Total revenues
View metricPEMAZYRE — Total revenues
View metricTABRECTA Royalty Revenues — Total revenues
View metricReportable Segment — Research and development - internal
View metricOPZELURA — Total revenues
View metricBusiness Overview
Competitive Position
A leading player in the JAK inhibitor space with a dominant market position in myelofibrosis and polycythemia vera treatments.
Geographies
United States, Europe, Japan, Canada
Customer Segments
Patients with rare diseases, Healthcare providers, Specialty distributors
Upstream Dependencies
Contract manufacturing organizations, Raw material suppliers, Clinical research organizations
Downstream Customers
Specialty pharmacy providers, Pharmaceutical wholesalers, Government healthcare programs, Private insurers
Competitors & Partners
Competitors
AbbVie
ABBV
Competitor in oncology and immunology therapeutics.
Gilead Sciences
GILD
Competitor in the development of JAK inhibitors and oncology treatments.
Bristol-Myers Squibb
BMY
Competitor in the hematology and oncology space with competing JAK inhibitors and immunotherapies.
Pfizer
PFE
Competitor in the kinase inhibitor and inflammation markets.
Partners
Novartis
NVS
Collaboration partner for the development and commercialization of ruxolitinib (JAKAVI) outside the United States.
MorphoSys AG
MOR
Collaboration partner for the development and commercialization of tafasitamab (MONJUVI).
Syndax Pharmaceuticals
SNDX
Collaboration partner for the development and commercialization of axatilimab (NIKTIMVO).
Eli Lilly
LLY
Collaboration partner for baricitinib (OLUMIANT).
Subsidiaries
Incyte Biosciences Europe Sàrl
European headquarters and operational hub for international commercialization.
ARIAD Pharmaceuticals (European Operations)
Acquired operations providing the license for ICLUSIG in Europe.
Incyte FAQ
Common questions about Incyte
Incyte is a global biopharmaceutical company specializing in the discovery, development, and commercialization of proprietary therapeutics. The company focuses on three core therapeutic areas: Hematology, Oncology, and Inflammation and Autoimmunity. Its primary value proposition lies in its ability to bring first-in-class and best-in-class treatments to market for rare blood cancers and immune-related conditions.
Incyte (INCY) has a market capitalization of $19.5B and trades on NASDAQ.
Incyte generated $5.4B in trailing twelve-month revenue with net income of $1.4B, representing a net margin of 26.7%. Gross margin stands at 92.5%. These figures are based on the Q1 2026 filing.
Incyte's key competitors include AbbVie, Gilead Sciences, Bristol-Myers Squibb, and others. These companies compete in similar markets and product categories.
Incyte has approximately 2,524 employees.